Emerging evidence suggests that low-dose ketamine can significantly reduce anxiety symptoms. Multiple clinical studies have demonstrated rapid anxiolytic effects, particularly in patients with comorbid depression and anxiety. In depression trials, anxiety subscale scores consistently improve alongside depressive symptoms within hours of a single infusion. However, research on ketamine for primary anxiety disorders without comorbid depression remains limited, and its use for anxiety is considered off-label.
What the Evidence Shows
Most of the evidence for ketamine's anxiolytic effects comes from depression studies where anxiety was measured as a secondary outcome. Meta-analyses have found that ketamine produces statistically significant reductions in anxiety measures, including the Hamilton Anxiety Rating Scale (HAM-A), at 24 hours to 7 days post-infusion. These effects are observed even after controlling for improvements in depressive symptoms, suggesting a direct anxiolytic action rather than simply a byproduct of mood improvement.
For specific anxiety disorders, the research base is smaller but encouraging. Glue and colleagues (2017) conducted a dose-ranging study of subcutaneous ketamine in patients with generalized anxiety disorder and social anxiety disorder, finding significant anxiolytic effects at doses of 0.5 and 1.0 mg/kg that persisted for up to 14 days. A 2018 study by Taylor and colleagues found that repeated ketamine infusions reduced anxiety in patients with treatment-resistant generalized anxiety disorder.
How Ketamine May Reduce Anxiety
Ketamine's anxiolytic mechanism likely involves several pathways. By modulating glutamate signaling and promoting neuroplasticity in the prefrontal cortex and amygdala, ketamine may help restore healthy fear-regulation circuits that are disrupted in anxiety disorders. The rapid formation of new synaptic connections could help re-establish top-down prefrontal control over amygdala-driven anxiety responses.
Additionally, ketamine's effects on GABA interneuron signaling and its modulation of the default mode network -- a brain network associated with rumination and self-referential thinking -- may contribute to anxiety reduction by interrupting patterns of anxious worry and catastrophic thinking.
It is important to note that ketamine treatment itself can temporarily increase anxiety during the infusion due to its dissociative effects, particularly in anxious patients. Proper preparation, a calming treatment environment, and experienced clinical staff help manage this.
For more on ketamine's therapeutic applications, see the Ketamine for Depression Comprehensive Guide.
References
- PubMed: Ketamine for Anxiety: A Systematic Review — Systematic review of ketamine's anxiolytic effects across clinical studies
- PubMed: Ascending Single-Dose Study of Subcutaneous Ketamine in Anxiety Disorders — Glue et al. dose-ranging study in GAD and social anxiety
- NIMH: Anxiety Disorders Overview — National Institute of Mental Health information on anxiety disorders and treatment research
Share